Stereotaxis, Inc.
2.9200-0.05 (-1.68%)
Oct 29, 4:00:00 PM EDT · NYSE American · STXS · USD
Key Stats
Market Cap
265.92MP/E (TTM)
-Basic EPS (TTM)
-0.29Dividend Yield
0%Recent Filings
8-K
ATM stock sales pact
Stereotaxis inked a sales agreement with Roth Capital on August 29, 2025, enabling at-the-market offerings of up to $50 million in common stock. Proceeds will fuel working capital, R&D, and faster rollout of its innovation pipeline. No sales are guaranteed; it hinges on market vibes and company needs. This bolsters liquidity amid growth pushes.
10-Q
Q2 FY2025 results
Stereotaxis posted Q2 revenue of $8.8 million, up 95% year-over-year from $4.5 million, fueled by $3.0 million in systems sales versus $0.2 million last year, while disposables, service, and accessories climbed 35% to $5.8 million, aided by post-acquisition contributions from APT. Gross margin dipped to 52% from 74%, reflecting product mix shifts and fair-value inventory adjustments from the July 2024 APT buyout, which added $3.8 million in goodwill and $7.0 million in amortizable intangibles over 7-10 years. Operating loss narrowed to $4.0 million from $6.0 million, with net loss at $3.8 million or $(0.05) diluted EPS on 88 million shares—consistent with basic, no anti-dilution flagged. Cash burned $5.5 million YTD to end at $7.0 million, with free cash flow not disclosed in the 10-Q; no debt burdens the balance sheet. APT integration bolsters catheter innovation. Supply chain snarls from tariffs and geopolitics pose ongoing hurdles.
8-K
Q2 revenue jumps 95%
Stereotaxis reported Q2 2025 revenue of $8.8 million, surging 95% year-over-year on $3.0 million in system sales—including the first commercial GenesisX—and 35% recurring revenue growth to $5.8 million from new launches like MAGiC and Map-iT. Gross margins hit 52%, while adjusted operating loss narrowed to $1.4 million amid lower expenses and a $0.5 million tax credit. Revenue doubled, yet margins lag from acquisition costs. The company eyes double-digit full-year growth, bolstered by July's $12.5 million financing.
8-K
Q2 revenue surges 90% YoY
Stereotaxis announced preliminary Q2 2025 revenue of $8.5 million to $8.8 million, surging 90% year-over-year from Q2 2024 while climbing 15% sequentially from Q1 2025, fueled by gains in both recurring and system streams. Gross margins hold steady or tick up from Q1 levels, but GAAP operating expenses loom at $8.2 million to $8.8 million. Revenue beats expectations. Final figures await August's earnings call, with risks from quarter-end adjustments potentially altering outcomes.
8-K
Stereotaxis prices $12.5M stock offering
Stereotaxis entered a registered direct offering on July 17, 2025, to sell 6.25 million shares at $2.00 each, led by a strategic partner and institutional investors. Initial closing of 4.25 million shares for $8.5 million gross proceeds occurs July 18, with an additional $4.0 million closing by November 25. Funds will accelerate product commercialization, R&D, and working capital. Yet closing conditions persist.
IPO
Website
Employees
Sector
Industry
BAX
Baxter International Inc.
22.42-0.44
BDX
Becton, Dickinson and Company
181.52-2.69
BSX
Boston Scientific Corporation
100.30-0.67
ISRG
Intuitive Surgical, Inc.
537.59-7.80
MBOT
Microbot Medical Inc.
2.13-0.06
MMSI
Merit Medical Systems, Inc.
81.39-1.40
SSII
SS Innovations International In
8.65+0.13
STE
STERIS plc (Ireland)
236.79-4.41
SYK
Stryker Corporation
369.59-6.34
VTAK
Catheter Precision, Inc.
2.44-0.12